Market PotentialSAT-3247 shows therapeutic potential in dogs with golden retriever muscular dystrophy, a recognized model for Duchenne muscular dystrophy.

Regulatory MilestonesSAT-3247 received Rare Pediatric Disease Designation by the FDA for the treatment of DMD.

Bears Say

Enrollment ChallengesManagement expects to complete enrollment of the SAD and MAD cohorts by YE2024 and 1Q25, respectively, indicating progress in clinical trials.

Financial OutlookSatellos expects to report SAD and MAD data in 1Q25, which could be a catalyst for the stock.

RisksRisks identified include clinical, regulatory, commercial, competition, and dilution.

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

23.54% Insiders

― Mutual Funds

― Other Institutional Investors

76.46% Public Companies and

Individual Investors

Detailed Ownership Overview >

MSCLF FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was $0.27 and its highest was $0.94 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is $79.69M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on Nov 13, 2024. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of -$0.035 by -$0.021.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.03.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 153,375,400 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -$0.056 in its last earnings report, missing expectations of -$0.035. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in MSCLF

---

Satellos Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

-84.66%

Trailing 12-Months

Asset Growth

-50.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.

---

MSCLF Stock 12 Month Forecast

Average Price Target

$0.88

▲(60.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.88117875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.88117875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Apr<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5662445192307692,0.5924890384615384,0.6187335576923078,0.644978076923077,0.6712225961538462,0.6974671153846154,0.7237116346153847,0.7499561538461539,0.7762006730769231,0.8024451923076923,0.8286897115384615,0.8549342307692307,{"y":0.88117875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5661538461538462,0.5923076923076923,0.6184615384615385,0.6446153846153846,0.6707692307692308,0.696923076923077,0.7230769230769232,0.7492307692307693,0.7753846153846153,0.8015384615384615,0.8276923076923077,0.8538461538461539,{"y":0.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5662445192307692,0.5924890384615384,0.6187335576923078,0.644978076923077,0.6712225961538462,0.6974671153846154,0.7237116346153847,0.7499561538461539,0.7762006730769231,0.8024451923076923,0.8286897115384615,0.8549342307692307,{"y":0.88117875,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.24,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.35,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.33,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.38,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.51,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Oncolytics Biotech

―

THTX

Theratechnologies

―

Compare MSCLF Stocks >

Best Analysts Covering MSCLF

1 Year

Arthur He CFAH.C. Wainwright

1 Year Success Rate

5/6 ratings generated profit

1 Year Average Return

+35.55%

reiterated a buy rating 3 months ago

Copying Arthur He CFA's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +35.55% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Satellos Bioscience (MSCLF) Price & Analysis

MSCLF Stock Chart & Stats

Satellos Bioscience News

Bulls Say, Bears Say

Financials

Options Prices

Ownership Overview

MSCLF FAQ

Satellos Bioscience Stock Smart Score

Analyst Consensus

Insider Transactions

News Sentiment

Technicals

Fundamentals

Company Description

Satellos Bioscience

MSCLF Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering MSCLF

Become an Expert with TipRanks Premium